Literature DB >> 34940818

Diagnosed with myeloma before age 40.

Ola Landgren1, Dickran Kazandjian1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34940818      PMCID： PMC8703364          DOI： 10.1182/blood.2021013539

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Dominik Dytfeld; Sebastian Grosicki; Philippe Moreau; Naoki Takezako; Mitsuo Hori; Xavier Leleu; Richard LeBlanc; Kenshi Suzuki; Marc S Raab; Paul G Richardson; Mihaela Popa McKiver; Ying-Ming Jou; Suresh G Shelat; Michael Robbins; Brian Rafferty; Jesús San-Miguel
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

2.  Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.

Authors:  Hans C Lee; Noopur S Raje; Ola Landgren; Vijay V Upreti; Jin Wang; Ariel A Avilion; Xuguang Hu; Erik Rasmussen; Gataree Ngarmchamnanrith; Hisaki Fujii; Andrew Spencer
Journal:  Leukemia       Date:  2020-04-21       Impact factor: 11.528

3.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Authors:  Michel Attal; Paul G Richardson; S Vincent Rajkumar; Jesus San-Miguel; Meral Beksac; Ivan Spicka; Xavier Leleu; Fredrik Schjesvold; Philippe Moreau; Meletios A Dimopoulos; Jeffrey Shang-Yi Huang; Jiri Minarik; Michele Cavo; H Miles Prince; Sandrine Macé; Kathryn P Corzo; Frank Campana; Solenn Le-Guennec; Franck Dubin; Kenneth C Anderson
Journal:  Lancet       Date:  2019-11-14       Impact factor: 79.321

4.  A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Joseph Mikhael; Paul Richardson; Saad Z Usmani; Noopur Raje; William Bensinger; Chatchada Karanes; Frank Campana; Dheepak Kanagavel; Franck Dubin; Qianying Liu; Dorothée Semiond; Kenneth Anderson
Journal:  Blood       Date:  2019-03-12       Impact factor: 22.113

5.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.

Authors:  Parneet K Cheema; Sahar Zadeh; Vishal Kukreti; Donna Reece; Christine Chen; Suzanne Trudel; Joseph Mikhael
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-09       Impact factor: 5.742

7.  Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Authors:  Heinz Ludwig; Brian G M Durie; Vanessa Bolejack; Ingemar Turesson; Robert A Kyle; Joan Blade; Rafael Fonseca; Meletios Dimopoulos; Kazuyuki Shimizu; Jesus San Miguel; Jan Westin; Jean-Luc Harousseau; Meral Beksac; Mario Boccadoro; Antonio Palumbo; Bart Barlogie; Chaim Shustik; Michele Cavo; Philip R Greipp; Douglas Joshua; Michel Attal; Pieter Sonneveld; John Crowley
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

8.  Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Authors:  Alexis Caulier; Murielle Roussel; Pierre Morel; Naelle Lombion; Benoît Branco; Jean Galtier; Cyrille Hulin; Aurore Perrot; Valentine Richez; Anne-Victoire Michaud; Cyrille Touzeau; Chantal Doyen; Clara Mariette; Denis Caillot; Stéphanie Harel; Pascal Lenain; Sarah Ivanoff; Jean Fontan; Anne-Marie Stoppa; Salomon Manier; Laurent Garderet; Xavier Leleu; Jean-Pierre Marolleau; Bertrand Arnulf; Hervé Avet-Loiseau; Bruno Royer
Journal:  Blood       Date:  2021-12-23       Impact factor: 22.113

9.  Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

Authors:  Efstathios Kastritis; Evangelos Terpos; Maria Roussou; Maria Gavriatopoulou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Despoina Fotiou; Dimitrios Ziogas; Ioannis Panagiotidis; Eftychia Kafantari; Stavroula Giannouli; Athanasios Zomas; Konstantinos Konstantopoulos; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.